Price
CHART BY
Frequently asked questions
What is Veru's market capitalization?
What is the Earnings Per Share (EPS) for Veru?
What are the analyst ratings and target price for Veru's stock?
What is Veru's revenue over the trailing twelve months?
What is the EBITDA for Veru?
What is the free cash flow of Veru?
How many employees does Veru have, and what sector and industry does it belong to?
What is the free float of Veru's shares?
Financials
- Market Cap
- $95.02M
- EPS (TTM)
- -$0.284
- Free Float
- 125.73M
- Revenue (TTM)
- $16.89M
- EBITDA (TTM)
- -$37.87M
- Free Cashflow (TTM)
- -$21.84M
Pricing
- 1D span
- $0.655$0.68
- 52W span
- $0.36$1.92
Analyst Ratings
The price target is $4.00 and the stock is covered by 4 analysts.
Buy
4
Hold
0
Sell
0
Information
Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed for two indications: (i) Phase 2b clinical study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness and (ii) subject to the availability of sufficient funding, Phase 3 clinical trial of enobosarm for the treatment of androgen receptor positive (AR+), estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The company was founded by William R. Gargiulo, Jr., O. B. Parrish, and Harry Fisch in 1971 and is headquartered in Miami, FL.
- Employees
- 210
- Industries
- Pharmaceuticals: Major
- Sector
- Health Care
Identifier
- ISIN
- US92536C1036
- Primary Ticker
- VERU